C HAPTER 43: D RUGS U SED TO T REAT C ANCER
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
MULTIPLE CHOICE
1. Which s ymptom is the patient who is receiving bleom ycin (Blenoxane)
therapy most likel y to exhibit?
a. Increased respiratory rate and cough
b. Weight gain and peripheral edem a
c. Numbness and tingling of hands and feet
d. Lethargy and orthostatic hypotension
ANS: A
Compromised respiratory function may occur in patients receiving bleom ycin
therapy. Increased respiratory rate and cough can be signs that further
problems are developing, such as heart failure. Bleom ycin does not cause
weight gain, peripheral edema, numbness and tingling of hands and feet,
lethargy, or orthostatic hypotension.
DIF: Cognitive Level: Comprehension REF: p. 701 | p. 702
OBJ: 5
NAT: NCLEX Client Needs Category: Physiological Integrit y
TOP: Nursing Process Step: Assessment CON: Clinical Judgment |
Safet y
2. Which rationale describes the purpose of administering filgrastim
(Neupogen) to a patient who is post -bowel resection resulting from ca ncer?
a. Decreases the gastrointestinal (GI) toxicity resulting from
chemotherapeutic agents.
, b. Suppresses the immune response.
c. Works as an antiemetic and stimulate his appetite.
d. Increases the white blood cell (WBC) counts.
ANS: D
Filgrastim works to stimulate WBC production and decrease the incidence of
infection. Filgrastim is a colony stimulating factor, which stimulates WBC
proliferation and maturation. It is particularl y helpful for patients prone to
neutropenia resulting from cancer therapy. Fi lgrastim does not affect GI
toxicit y, suppress immune response (it works to enhance it), or affect
appetite or nausea.
DIF: Cognitive Level: Comprehension REF: p. 704 OBJ: 3
NAT: NCLEX Client Needs Category: Health Promotion and
Maintenance
TOP: Nursing Process Step: Implementation
CON: Clinical Judgment
3. Which outcome is intended with the use of the chemoprotective drug
amifostine (Ethyol)?
a. Decreased nausea and vomiting
b. Increased effectiveness of the chemotherapy
c. Maintenance of body weight
d. Decreased renal toxicit y
ANS: D
Amifostine is used to reduce the cumulative renal toxicit y associated with the
repeated administration of cisplatin in patients with advanced ovarian cancer.
Chemoprotective drugs do not decrease nausea and vomiting, enhance the
effectiveness of chemotherapy treatment, or help prevent weight loss.
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
MULTIPLE CHOICE
1. Which s ymptom is the patient who is receiving bleom ycin (Blenoxane)
therapy most likel y to exhibit?
a. Increased respiratory rate and cough
b. Weight gain and peripheral edem a
c. Numbness and tingling of hands and feet
d. Lethargy and orthostatic hypotension
ANS: A
Compromised respiratory function may occur in patients receiving bleom ycin
therapy. Increased respiratory rate and cough can be signs that further
problems are developing, such as heart failure. Bleom ycin does not cause
weight gain, peripheral edema, numbness and tingling of hands and feet,
lethargy, or orthostatic hypotension.
DIF: Cognitive Level: Comprehension REF: p. 701 | p. 702
OBJ: 5
NAT: NCLEX Client Needs Category: Physiological Integrit y
TOP: Nursing Process Step: Assessment CON: Clinical Judgment |
Safet y
2. Which rationale describes the purpose of administering filgrastim
(Neupogen) to a patient who is post -bowel resection resulting from ca ncer?
a. Decreases the gastrointestinal (GI) toxicity resulting from
chemotherapeutic agents.
, b. Suppresses the immune response.
c. Works as an antiemetic and stimulate his appetite.
d. Increases the white blood cell (WBC) counts.
ANS: D
Filgrastim works to stimulate WBC production and decrease the incidence of
infection. Filgrastim is a colony stimulating factor, which stimulates WBC
proliferation and maturation. It is particularl y helpful for patients prone to
neutropenia resulting from cancer therapy. Fi lgrastim does not affect GI
toxicit y, suppress immune response (it works to enhance it), or affect
appetite or nausea.
DIF: Cognitive Level: Comprehension REF: p. 704 OBJ: 3
NAT: NCLEX Client Needs Category: Health Promotion and
Maintenance
TOP: Nursing Process Step: Implementation
CON: Clinical Judgment
3. Which outcome is intended with the use of the chemoprotective drug
amifostine (Ethyol)?
a. Decreased nausea and vomiting
b. Increased effectiveness of the chemotherapy
c. Maintenance of body weight
d. Decreased renal toxicit y
ANS: D
Amifostine is used to reduce the cumulative renal toxicit y associated with the
repeated administration of cisplatin in patients with advanced ovarian cancer.
Chemoprotective drugs do not decrease nausea and vomiting, enhance the
effectiveness of chemotherapy treatment, or help prevent weight loss.
